These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 33073552)

  • 21. Efficacy of Lopinavir/Ritonavir Compared With Standard Care for Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review.
    Hariyanto TI; Kristine E; Jillian Hardi C; Kurniawan A
    Infect Disord Drug Targets; 2021; 21(5):e270421187364. PubMed ID: 33121422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meta-analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019.
    Yu M; Wang DC; Li S; Lei YH; Wei J; Huang LY
    J Med Virol; 2022 Apr; 94(4):1513-1522. PubMed ID: 34837230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.
    Joseph BA; Dibas M; Evanson KW; Paranjape G; Vegivinti CTR; Selvan PT; Saravu K; Gupta N; Pulakurthi YS; Keesari PR; Varsha S; Chittajallu S; Dmytriw AA; Reierson NL; Mikoff N; Kamrowski S; Schmidt M; Davis AR; Pederson JM; Mishra HK; Touchette JC; Kallmes K
    Expert Rev Anti Infect Ther; 2021 Jun; 19(6):679-687. PubMed ID: 33187459
    [No Abstract]   [Full Text] [Related]  

  • 24. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
    Choudhury M; Dhanabalan AK; Goswami N
    J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.
    Vernaz N; Agoritsas T; Calmy A; Gayet-Ageron A; Gold G; Perrier A; Picard F; Prendki V; Reny JL; Samer C; Stirnemann J; Vetter P; Zanella MC; Zekry D; Baggio S
    Swiss Med Wkly; 2020 Dec; 150():w20446. PubMed ID: 33382449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biggest COVID-19 trial tests repurposed drugs first.
    Nat Biotechnol; 2020 May; 38(5):510. PubMed ID: 32393915
    [No Abstract]   [Full Text] [Related]  

  • 27. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study.
    Giacomelli A; Pagani G; Ridolfo AL; Oreni L; Conti F; Pezzati L; Bradanini L; Casalini G; Bassoli C; Morena V; Passerini S; Rizzardini G; Cogliati C; Ceriani E; Colombo R; Rusconi S; Gervasoni C; Cattaneo D; Antinori S; Galli M
    J Med Virol; 2021 Mar; 93(3):1421-1427. PubMed ID: 32776534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis.
    Amani B; Khanijahani A; Amani B; Hashemi P
    J Pharm Pharm Sci; 2021; 24():246-257. PubMed ID: 34048671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic review and meta-analysis of efficacy and safety of hydroxychloroquine and chloroquine in the treatment of COVID-19.
    Mittal N; Mittal R; Gupta MC; Kaushal J; Chugh A; Khera D; Singh S
    J Family Med Prim Care; 2021 Jun; 10(6):2126-2139. PubMed ID: 34322403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
    Kalantari S; Fard SR; Maleki D; Taher MT; Yassin Z; Alimohamadi Y; Minaeian S
    J Med Virol; 2021 Dec; 93(12):6557-6565. PubMed ID: 34255369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
    Olagunju A; Fowotade A; Olagunoye A; Ojo TO; Adefuye BO; Fagbamigbe AF; Adebiyi AO; Olagunju OI; Ladipo OT; Akinloye A; Adeagbo BA; Onayade A; Bolaji OO; Happi C; Rannard S; Owen A
    Trials; 2021 Jan; 22(1):3. PubMed ID: 33397457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials.
    Patel TK; Patel PB; Barvaliya M; Saurabh MK; Bhalla HL; Khosla PP
    J Infect Public Health; 2021 Jun; 14(6):740-748. PubMed ID: 34020215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review.
    Qomara WF; Primanissa DN; Amalia SH; Purwadi FV; Zakiyah N
    Int J Gen Med; 2021; 14():8557-8571. PubMed ID: 34849001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study.
    Prats-Uribe A; Sena AG; Lai LYH; Ahmed WU; Alghoul H; Alser O; Alshammari TM; Areia C; Carter W; Casajust P; Dawoud D; Golozar A; Jonnagaddala J; Mehta PP; Gong M; Morales DR; Nyberg F; Posada JD; Recalde M; Roel E; Shah K; Shah NH; Schilling LM; Subbian V; Vizcaya D; Zhang L; Zhang Y; Zhu H; Liu L; Cho J; Lynch KE; Matheny ME; You SC; Rijnbeek PR; Hripcsak G; Lane JC; Burn E; Reich C; Suchard MA; Duarte-Salles T; Kostka K; Ryan PB; Prieto-Alhambra D
    BMJ; 2021 May; 373():n1038. PubMed ID: 33975825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial.
    Reis G; Moreira Silva EADS; Medeiros Silva DC; Thabane L; Singh G; Park JJH; Forrest JI; Harari O; Quirino Dos Santos CV; Guimarães de Almeida APF; Figueiredo Neto AD; Savassi LCM; Milagres AC; Teixeira MM; Simplicio MIC; Ribeiro LB; Oliveira R; Mills EJ;
    JAMA Netw Open; 2021 Apr; 4(4):e216468. PubMed ID: 33885775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).
    Shah S; Das S; Jain A; Misra DP; Negi VS
    Int J Rheum Dis; 2020 May; 23(5):613-619. PubMed ID: 32281213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
    Zekarias A; Watson S; Vidlin SH; Grundmark B
    Drug Saf; 2020 Dec; 43(12):1309-1314. PubMed ID: 32978702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic.
    Kheirabadi D; Haddad F; Mousavi-Roknabadi RS; Rezaeisadrabadi M; Dehghan H; Fazlzadeh A
    J Med Virol; 2021 May; 93(5):2705-2721. PubMed ID: 33463727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.